Search

Displaying results 5861 - 5870 of 7540 in total
  1. Drug

    EB05

    go.drugbank.com/drugs/DB16477
    Investigational

    EB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS.

  2. Drug

    Neramexane

    go.drugbank.com/drugs/DB04926
    Investigational

    Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.

  3. Drug

    Clorobiocin

    go.drugbank.com/drugs/DB03966
    Experimental

    Clorobiocin is an aminocoumarin antibiotic, similar to [novobiocin] and coumermycin A1.

  4. Drug

    CX157

    go.drugbank.com/drugs/DB05205
    Investigational

    CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous

  5. Drug

    MP4

    go.drugbank.com/drugs/DB05313
    Investigational

    MP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. … It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.

  6. Drug

    MW33

    go.drugbank.com/drugs/DB16358
    Experimental

    MW33 is a recombinant fully human antibody to SARS-CoV-2. … [L27411] This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).

  7. Drug

    ABT-072

    go.drugbank.com/drugs/DB15156
    Investigational

    ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat

  8. Drug

    Cilomilast

    go.drugbank.com/drugs/DB03849
    Investigational

    Following four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile.

  9. Drug

    Ganulameran

    go.drugbank.com/drugs/DB16442
    Investigational

    The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.

  10. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor.